Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Clears Gilead’s Regulatory Path For Three New Chemical Entities In HIV

This article was originally published in The Pink Sheet Daily

Executive Summary

Also waiting for agency word on its appeal to a “complete response” letter for aztreonam lysine in cystic fibrosis.

You may also be interested in...



Back To The Future: Gilead Signs Up Four Indian Companies To License Late-stage AIDS Therapies

MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development

Gilead/J&J Collaboration Seeks To Create Triple-Therapy Successor To Atripla

The opportunity for J&J's investigative non-nucleoside reverse transcriptase inhibitor may come at the expense of BMS, Gilead's partner on Atripla.

Gilead/J&J Collaboration Seeks To Create Triple-Therapy Successor To Atripla

The opportunity for J&J's investigative non-nucleoside reverse transcriptase inhibitor may come at the expense of BMS, Gilead's partner on Atripla.

Related Content

Topics

UsernamePublicRestriction

Register

PS068526

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel